Literature DB >> 33431288

The New Virus Tells the Old Story.

Eric Goldschmidt1, Fedor Lurie2.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 33431288      PMCID: PMC8970658          DOI: 10.1016/j.ejvs.2020.12.014

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


× No keyword cloud information.
Vision is a dominant sense in the majority of humans. This fact explains our bias as physicians towards ordering imaging tests. Despite a common understanding that imaging is never 100% accurate, the reliance on these tests as the first diagnostic step is hard to overcome. Duplex ultrasound (DUS) to diagnose acute deep vein thrombosis (DVT) provides a good example. With false positive and negative rates approaching 6% and exceeding 10%, respectively, evidence based guidelines strongly recommend against DUS as a first line diagnostic test. Nevertheless, the widespread practice of relying on DUS remains unchanged. The COVID-19 pandemic has introduced a new challenge to such practice. Thrombo-inflammation, one of the main pathophysiological features of this new disease contributes to the high incidence of venous thrombo-embolism (VTE) in infected individuals, and the role of traditional risk factors for thrombo-embolism has become less clear. The present study by Bellmunt and colleagues set out to investigate VTE incidence in a cohort of 230 critically ill ICU patients with confirmed COVID-19, as well as to determine whether a single DUS can detect the presence of DVT before the development of pulmonary embolism (PE). Although the authors confirmed a high incidence of VTE (approximately 25%, findings similar to the 30% pooled rate of VTE in a recent meta-analysis), the lack of a comparison group means that the true increase can only be inferred; historical rates of VTE in ICU patients with non-COVID viral pneumonias are lower than 2%. More importantly, screening DUS did not improve outcomes. Six patients with negative scans developed symptomatic VTE within seven days after scan. The reason early detection failed to prevent future VTE events is difficult to determine but can be partially explained by another significant finding of this study: the similar rates of VTE in patients regardless of anticoagulation dosing. A longer follow up, therefore, may reveal even more new VTE events. In contrast, D dimer levels were predictive of future VTE events. A cut off value of 1 500 ng/mL had 86% negative predictive value and using a higher cut off value was reported to be an even better predictor. As is common to all studies, more questions are raised than answered. The study showed that decisions based on clinical manifestations and D dimer levels outperform a single screening DUS in critically ill patients with COVID-19; however, how best to risk stratify patients and implement the appropriate treatment remains unclear.
  4 in total

Review 1.  Measurement of the clinical and cost-effectiveness of non-invasive diagnostic testing strategies for deep vein thrombosis.

Authors:  S Goodacre; F Sampson; M Stevenson; A Wailoo; A Sutton; S Thomas; T Locker; A Ryan
Journal:  Health Technol Assess       Date:  2006-05       Impact factor: 4.014

2.  Venous Thromboembolism in Hospitalized COVID-19 Patients.

Authors:  Gurusaravanan Kutti Sridharan; Radhakrishna Vegunta; Venkata Ram Pradeep Rokkam; Veeraraghavan Meyyur Aravamudan; Rathnamitreyee Vegunta; Shahab R Khan; Suresh Ponnada; Umesha Boregowda; Kalyan Prudhvi; Gajapathiraju Chamarthi; Babu P Mohan
Journal:  Am J Ther       Date:  2020 Nov/Dec       Impact factor: 2.688

3.  COVID-19 Infection in Critically Ill Patients Carries a High Risk of Venous Thrombo-embolism.

Authors:  Sergi Bellmunt-Montoya; Claudia Riera; Daniel Gil; Manuela Rodríguez; Marvin García-Reyes; Lucía Martínez-Carnovale; Carlos Marrero; Miquel Gil; Juan Carlos Ruiz-Rodríguez; Ricard Ferrer; Miriam de Nadal; Manel Monreal; Secundino Llagostera
Journal:  Eur J Vasc Endovasc Surg       Date:  2020-12-23       Impact factor: 7.069

4.  Thrombosis in hospitalized patients with viral respiratory infections versus COVID-19.

Authors:  Nathaniel R Smilowitz; Varun Subashchandran; Eugene Yuriditsky; James M Horowitz; Harmony R Reynolds; Judith S Hochman; Jeffrey S Berger
Journal:  Am Heart J       Date:  2020-11-10       Impact factor: 4.749

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.